Aslan Pharmaceutical Ltd (ASLN) ADS Each Rep 5 Ord Shares
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. The Company's ASLAN004 is a fully human monoclonal antibody targeting the IL-13 receptor a1 subunit (IL-13Ra1). By targeting IL-13Ra1, which forms the Type II receptor complex with IL-4Ra, ASLAN004 inhibits signaling of both interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheeze and cough.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.